Adam Dingens, PhD, MS

I passed my thesis defense yesterday, “Understanding #SARSCoV2 antigenic drift using complete genotype-to-phenotype maps.” It has been an absolute privilege to be a graduate student in the @jbloom_lab at the @fredhutch and @UW_MSTP.

FL77 is hiring multiple roles across many experience levels. Come develop the next generation of vaccines at a cutting edge, rapidly growing, and well-funded startup! Please RT! linkedin.com/jobs/search/?f…

India’s COVID crisis flags need to forecast variants nature.com/articles/d4158…

Awesome to see more high-throughput antibody escape tech come on board, particularly from industry - where resulting data can more quickly be used to evaluate, engineer, and pool mAbs under clinical development. Great job @AAlphaBio !

Very happy to share that I wrote a review with Keith Jerome and Dan Stone (VIDD FHCRC) about the exciting developments in the field of AAV vector engineering to target organs/tissues that can harbor viral reservoirs! 🎉🎉🎉

We've created an interactive website to visualize >100,000 experimental measurements of how mutations to #SARSCoV2 RBD affect binding by antibodies & sera: jbloomlab.github.io/SARS2_RBD_Ab_e… Explore it to examine a wealth of information about the antigenic effects of viral mutations. (1/n)

Being published in @CellCellPress, this must be a cruel April Fools Joke. Having is behind a paywall is the kicker! cell.com/cell/fulltext/…

Come join my team at Shape TX, working at the interface of virology, functional genomics, and the next generation of RNA therapies! boards.greenhouse.io/shapetherapeut…

We have completely mapped #SARS_CoV_2 mutations that escape binding by LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) both alone & in cocktail with LY-CoV016 in a new study led by @tylernstarr w/ @AllieGreaney & @AdamDingens: biorxiv.org/content/10.110… (1/n)

Half a million Americans have died of COVID-19. I wrote for @NewYorker about what this terrible milestone tells us, and what we still have to learn. newyorker.com/science/elemen…

Today is a good day.

I've long advocated the use of DMS-approaches to understand escape from monoclonal and pooled antibodies during their development as antiviral therapeutics, as well as during viral surveillance to guide their clinical use. Here's a great example why! science.sciencemag.org/content/early/…

And finally linking Jesse's initial excellent summary (and preprint link!) I missed in the first tweet! twitter.com/jbloom_lab/sta…

Lastly, these data on BG505 Env trimer responses - and parallel unbiased mapping approaches - are of keen interest given these immunogens are currently being evaluated in multiple clinical trials. I'm excited to see what the binding and neutralizing responses in humans may be!

Our new work with @WardLab1 & PJ Klasse comparing the binding and neutralizing antibody responses to HIV Env elicited by BG505 SOSIP trimer immunization in rabbits is now available, and summarized here:

In a new study (biorxiv.org/content/10.110…), we have completely mapped mutations to #SARSCoV2 that escape human antibodies, and shown that these "escape maps" predict how virus evolves under antibody pressure & inform design of escape-resistant antibody cocktails. (1/12)